NEURAXPHARM
Neuraxpharm develops and commercializes branded and generic CNS pharmaceuticals and nutraceuticals for the treatment and prevention of CNS disorders in main European countries.
NEURAXPHARM
Social Links:
Industry:
Biotechnology Pharmaceutical
Founded:
1985-01-01
Address:
Langenfeld, Rheinland-Pfalz, Germany
Country:
Germany
Website Url:
http://www.neuraxpharm.com
Total Employee:
501+
Status:
Active
Contact:
+49 2173 10600
Email Addresses:
[email protected]
Technology used in webpage:
IPv6 YouTube Person Schema Gravatar Profiles Ubuntu PayPal Visa WooCommerce Add To Cart HubSpot CMS Hub WooCommerce Checkout
Similar Organizations
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Current Advisors List
Current Employees Featured
Acquisitions List
Date | Company | Article | Price |
---|---|---|---|
2020-01-23 | Easypharm | Easypharm acquired by Neuraxpharm | N/A |
Official Site Inspections
http://www.neuraxpharm.com Semrush global rank: 989.06 K Semrush visits lastest month: 35.03 K
- Host name: ec2-18-198-74-125.eu-central-1.compute.amazonaws.com
- IP address: 18.198.74.125
- Location: Frankfurt am Main Germany
- Latitude: 50.1188
- Longitude: 8.6843
- Timezone: Europe/Berlin
- Postal: 60313
More informations about "Neuraxpharm"
Home - Neuraxpharm, your CNS Specialist
Neuraxpharm is a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders.See details»
Executive Committee - Neuraxpharm
Neuraxpharm is prepared to help society create its own future. Together with our esteemed physicians, pharmacy partners, loyal customers and tireless patient organizations, we will find solutions for disorders of the central nervous …See details»
About Neuraxpharm - Neuraxpharm
Neuraxpharm is a European leader in pharmaceuticals for disorders affecting the central nervous system (CNS). We are specialists in this field since 1985 and our more than 35 years’ …See details»
PRESS RELEASE Neuraxpharm reports another year of sustained …
East and globally via partners in more than 50 countries. Neuraxpharm is backed by funds advised by Permira. Neuraxpharm manufactures many of its pharmaceutical products at …See details»
Neuraxpharm - Crunchbase Company Profile & Funding
Neuraxpharm is a Pharmaceutical Company. View contacts for Neuraxpharm to access new leads and connect with decision-makers. Neuraxpharm develops and commercializes branded and …See details»
Neuraxpharm reports another year of sustained growth and …
Nov 14, 2024 · Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, …See details»
NEURAXPHARM CORPORATE PRESENTATION - PharmaCompass
Neuraxpharm develops and commercializes branded and generic CNS pharmaceuticals and nutraceuticals related to the prevention of CNS indications Plans of further geographic …See details»
Neuraxpharm reports another year of sustained growth and …
Nov 14, 2024 · Neuraxpharm is a leading European specialty pharmaceutical company focused on the treatment of the central nervous system (CNS), including both psychiatric and …See details»
Neuraxpharm Arzneimittel - Crunchbase Company Profile & Funding
Neuraxpharm Arzneimittel is a leader in generic pharmaceutical products for the treatment of disorders of the central nervous system (CNS). Founded in 1985, the company is a trusted …See details»
Neuraxpharm - Apax Partners
Neuraxpharm is a leading European specialty pharmaceutical company focused on the treatment of central nervous system disorders (CNS). With over 100 CNS molecules, the company offers a wide range of effective, differentiated and …See details»
Neuraxpharm reports another year of sustained growth and …
Nov 14, 2024 · As part of an ongoing drive to optimize commercial efficiency and support continued growth, Neuraxpharm continually looks at ways to fine-tune the structure of its …See details»
Neuraxpharm Expands Operations into the Middle East
Oct 2, 2024 · Neuraxpharm’s move into the Middle East follows the opening of affiliates in Brazil and Mexico in 2023 and adds to the growing list of more than 20 European countries where …See details»
PRESS RELEASE Neuraxpharm announces closing of acquisition of ...
Feb 1, 2023 · Neuraxpharm announces closing of acquisition of established products from Sanofi Düsseldorf and Barcelona – February 1, 2023 – Neuraxpharm Group (Neuraxpharm), a …See details»
Neuraxpharm - Contacts, Employees, Board Members, Advisors
Neuraxpharm has 6 current employee profiles, including CEO Jörg Thomas Dierks. Neuraxpharm has 1 board member or advisor, David Bruckmann.See details»
Permira funds to acquire leading European CNS specialty …
With its unique understanding of the CNS market built over 35 years, Neuraxpharm develops and commercializes value-added medicines and consumer healthcare products for chronic patients …See details»
Our commitment - Neuraxpharm
The overall corporate social responsibility capability for the whole group, providing broader and, in many cases, holistic support to healthcare professionals, patients and their families, is our key …See details»
Neuraxpharm Information - RocketReach
Neuraxpharm is a leading European specialty pharmaceutical company focused on the treatment of the central nervous system (CNS), including both psychiatric and neurological disorders. It …See details»
Neuraxpharm Group - Overview, News & Similar companies
View Neuraxpharm Group (www.neuraxpharm.com) location in Nordrhein-Westfalen, Germany , revenue, industry and description. Find related and similar companies as well as employees …See details»
Neuraxpharm - Funding, Financials, Valuation & Investors
Jan 23, 2020 · Neuraxpharm has acquired Easypharm on Jan 23, 2020. Which types of acquisition does this organization make most frequently? Neuraxpharm is a Pharmaceutical …See details»
RCSB PDB - 8YKM: Crystal structure of SARS-Cov-2 main protease …
Mar 5, 2024 · Main proteases (M pro s) are a class of conserved cysteine hydrolases among coronaviruses and play a crucial role in viral replication. Therefore, M pro s are ideal targets …See details»